Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs) Preliminary clinical data and KO-2806 development plans to be presented in October 2025 in conjunction with the ESMO Congress 2025 SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KUR...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on September 2, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 82,950 shares of common stock to seven (7) new employees under the Company...
Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program September 16 event to highlight preclinical data on the combination of FTI agents with multiple classes of targeted therapies October 18 event to review clinical data from the ESMO Congress 2025, including first clinical data from KO-2806 SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for cancer, today announced it will host two virtual investor and analy...
Kura Oncology to Participate in Three Upcoming Investor Conferences SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in three investor conferences in September. Cantor Global Health ConferenceThursday, September 4, 20258:35 a.m. ET / 5:35 a.m. PT H.C. Wainwright 27th Annual Global Investment ConferenceMonday, September 8, 20251:00 p.m. ET / 10:00 a.m. PT Morgan Stanle...
Was That It?; Downgrading Discretionary and Energy Volatility finally picked up last Friday, and the S&P 500 (SPX) and Nasdaq 100 (QQQ) both gapped lower to close below their 20-day MAs for the first time in over three months. With that said, all of the major indexes (SPX, QQQ, DJI, IWM) rallied yesterday to fill their gaps from Friday and SPX and QQQ have reclaimed above their 20-day MAs; this is a bullish signal that suggests any further pullback is likely to be relatively shallow, and should ...
A director at Opko Health Inc bought 675,000 shares at 1.320USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.